Docetaxel Lipid Microsphere (DT-LM) for Injection in Chemotherapy Patients
Status:
Unknown status
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
Docetaxel Lipid Microsphere (DT-LM) is a novel proprietary delivery system of docetaxel
developed by Shenyang Pharmaceutical University. In this Phase I study, the DT-LM was
evaluated for the maximum tolerated dose (MTD) and dose limiting toxicity (DLT) in patients
with advance solid tumors. It was also evaluated for pharmacokinetic and anti-tumor effects
of DT-LM compared to commerical docetaxel.